30 closest matches · ranked by relevance
Leukemia
Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…
Chronic Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 participants
Myeloid Leukemia, Chronic
Primary: Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 — 45; 29; 75; 92 percentage of participants
Chronic Myelogenous Leukemia
Primary: Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months — 74 Participants
Leukemia, Pediatric
Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032
Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Event-free Survival Rate (EFS) — 21.3 Months
Leukemia
Primary: Number of Patients Showing a Reduction by at Least 50% of Peripheral Blood BCR-ABL/ABL Ratio Compared to the Individual Prevaccine Level — 22; 14 participants
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…
Leukemia
Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia, BCR-ABL1-Like · Central Nervous System Leukemia
Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
CML in Chronic Phase
Primary: Percentage of Participants With Molecular Response (MR4^0) at 18 Months — 38.3 Percentage of Participants
Chronic Myeloid Leukemia · Ph+ Acute Lymphoblastic Leukemia
Primary: Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) — 50.7; 70.3 percentage of participants
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants
Chronic Myelogenous Leukemia
Primary: Kaplan-Meier Estimates of Overall Survival (All Randomized Participants) — 98.9; 97.7; 96.0; 93.6 Percentage of participants
Myelogenous Leukemia, Chronic
Primary: Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation — 22.3; 44.3; 42.7 Percentage of participants — p=<0.0001
Leukemia
Primary: Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR) — 50.8 Percentage of participants
Chronic Myeloid Leukemia
Primary: Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1 — 70.0; 68.3 Percentage of Participants — p=0.667
Leukemia
Primary: Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate — 42; 1; 17; 1 participants
Lymphoblastic Leukemia, Acute
Primary: Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start…
Myeloproliferative Neoplasms
Primary: Number of Participants With Hematological Response, as Measured by Any One or More of the Following Response Assessments: IWG-MDS and IWG-MF Criteria as Accurate and…
Chronic Myeloid Leukemia
Primary: Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population — 77.4; 55.0; 9.5; 59.2 percentage of participants
Chronic Myelogenous Leukemia
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) - Part 1 — 1; 1; 0 Participants
Chronic Myelogenous Leukemia in Chronic Phase
Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) · Hypereosinophilic Syndrome
Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants
Chronic Myeloid Leukemia · Philadelphia-Positive Myeloid Leukemia
Primary: Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 — 36; 14 Participants
Chronic Myeloid Leukemia · Acute Lymphoblastic Leukemia
Primary: Summary of Nilotinib Non-compartmental PK Parameters: Cmax — 405.111; 402.715 ng/mL
Myeloid Leukemia, Chronic
Primary: Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months — 204; 177 Participants — p=0.0056
Philadelphia Chromosome Positive CML
Primary: Overall Survival — 89.2 percentage of participants
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years